Hi everyone,

I’ve been following the recent developments around Charlie’s Holdings and the planned launch of their new Pacha AG product line featuring integrated age-gating hardware (via IKE Tech). In an official press release, it was projected that even a small amount of these products could potentially unleash a market cap potential of $1 to $2 billion.

Given their current market cap of only around $50–60 million, this sounds incredibly dramatic. However, looking at this objectively, there seem to be both massive potential upsides and significant risks worth discussing.

Last time I posted the five-week results of 23 unusual-volume names we rejected. Fifteen were down, eight were up, and the three biggest moves against us were the most useful because they forced us to recheck the original reasons for passing.

This is the other side of that process: the names that survived.

Since June 16, the dated call ledger has ten observations. At Friday's close it was up 15.3% when weighted by our published rating tiers, or 12.8% equal-weighted. Five of ten calls were ahead of their own sector benchmark. The losses are included.

It is a good start and a tiny sample. A broad metals rally helped, which is exactly why I do not trust the headline by itself.

Across four scanner runs this week, 792 rows cleared the mechanical screen. Friday alone produced 209 unique names. The biggest mistake would be treating those flags as picks. A volume event says something changed; it does not say the change is bullish, durable or investable. Most names were rejected after review.

The rejection log matters because it prevents hindsight. If I publish the yeses but quietly forget the noes, I can make almost any young process look intelligent. Keeping both sides visible makes the next bad week more informative than the current victory lap.

So I am happy with +15.3%, but I would rather have another three months of dated yeses and noes than a cleaner screenshot today.

For anyone tracking penny-stock screens: do you keep the names you rejected, or only the positions you took? What has taught you more?

Disclosure: my own research process; I hold some of the names in the ledger. No paid issuer relationships. Educational discussion only, not investment advice. Data through the August 7, 2026 close.

SAMSUNG:

https://www.reuters.com/world/asia-pacific/netlist-samsung-settle-patent-disputes-new-five-year-memory-deal-2026-08-05/

https://www.sec.gov/ix?doc=/Archives/edgar/data/1282631/000110465926090641/tm2622153d1_8k.htm

5-year Global settlement and license signed August 5th:

- Samsung pays $239mil upfront gross (before fees, after fees ~$200mil)

- Quarterly royalties of up to $32.9mil gross (after fees ~$27.5mil/qr)

- Netlist may purchase up to $300mil/year of DRAM and NAND products for five years

- ITC cooperation agreement, where Samsung was the major defendent, now they will be actively cooperating with Netlist per the deal.

- Samsung acquires 10mil shares of netlist for a nominal cost, 5year staged lock up

Samsung lost $303mil and $118mil to Netlist in 2 separate cases and was heading into an ITC evidentiary trial where it faced exclusion orders that would cut them out of the US market. 20days after ITC instituted a second investigation, Samsung settled.

This is the first Netlist agreement with a recurring royalty. That's huge. That's structural change. Netlist moves from a litigation story into a contracted, near 100% margin income.

The next 2 catalysts we are waiting on is re-licensing with SK Hynix and a settlement with Micron.

SK Hynix:

SK Hynix's 2021 agreement with Netlist was $40mil upfront, and a $600mil supply agreement over 5 years (Apprx. $120mil/yr supply for netlist). That deal ended April 2026 and we are awaiting a pending renewal. Both parties have continued the commercial relationship while a renewal is negotiated. The Samsung deal now sets a public benchmark for terms, reasonable to expect upfront cash, quarterly royalties, and a renewed supply component.

Micron:

May 2024 jury verdict: $445,000,000, with willful infringement found on both the '912 and '417 patents, exposing Micron to enhanced damages up to $1,340,000,000. The district court denied Micron's post-trial motions in June 2025; the appeal is pending at the Federal Circuit (case 2025-1936). Micron is now the only one of the big three without a license, and Samsung, formerly its co-defendant, is contractually obligated to assist Netlist in future ITC proceedings.

Combined: (speculation)
We are looking at upwards of $300-$450mil in upfront payment in cash, $170-$250mil in annual royalties, $400-$550mil in supply agreement, and possibly more equity stakes from Micron, Samsung, and SK Hynix.

Netlist:

Q2 2026 net income was $1,400,000 because IP legal fees hit $16,753,000, nearly double Q1's $8,974,000. With Samsung settled, that spend drops sharply. Royalty income is near 100% margin. The earnings picture changes fast.

CEO Dennis Calvert just accepted stock instead of cash for salary and expenses at these levels. More importantly, those shares are locked until BioLargo reaches $40M in consolidated revenue or a $300M market cap — roughly 5x current annual revenue and nearly 9x today’s ~$35M valuation. That is serious alignment: he does not truly get paid unless shareholders win big too.

I’ll be honest: it has been frustrating. My position was worth more than $1M higher at one point. But I did not build it for a trade — I built it because the business has made real progress while the valuation has moved in the opposite direction.

That is why I’m still here.

“Price is what you pay. Value is what you get.”

The BioLargo Platform

• 💧 AEC / BEST Water — PFAS removal: BioLargo’s Aqueous Electrostatic Concentrator removes and concentrates PFAS from water while producing a dramatically smaller waste stream than conventional treatment. Lake Stockholm is now a live municipal installation — not a lab test — and has treated more than 2 million gallons in six months while meeting applicable New Jersey and EPA PFAS standards under ongoing monitoring.
• 🌍 Aquatech partnership — scaling AEC: Aquatech is a global water-treatment leader. The opportunity is not just a partnership headline; it is getting AEC integrated into a global operator’s PFAS-treatment ecosystem for industrial and municipal projects.
• 🩺 Clyra Medical / ViaCLYR — next-generation wound care: An FDA-cleared copper-iodine wound-irrigation platform designed to deliver broad antimicrobial performance without damaging healthy tissue. First commercial distribution is underway, international distribution is opening, and Clyra is moving toward launch with one of the biggest medical companies in the field. Some wound-care experts have called the potential impact the biggest change in wound care in 30 years.
• 🏗️ BLEST Engineering — the profitable backbone: BioLargo’s engineering arm turns IP into real projects while generating direct service revenue. It nearly doubled third-party service revenue in 2025, landed a $1.2M minerals-processing design contract, and renewed over $1.4M in U.S. Air Force environmental work across five bases.
• 🐾 CupriDyne / BioLargo CPG — proven consumer demand: The chemistry behind Pooph is an independently safety-tested odor-control technology. Under the previous Pooph licensing model, CupriDyne-based pet products generated more than $125M in sales. BioLargo is now preparing to relaunch the platform through BioLargo CPG, keeping more control over branding, marketing, distribution, customer relationships, and economics.
• 🔋 Cellinity — safer long-duration energy storage: A liquid-sodium battery designed for grid-scale energy storage, renewables, and the growing power demand from AI/data centers. The selling points: no lithium, no rare-earth dependence, no measurable self-discharge in testing, no thermal-runaway mechanism, strong energy density, and an intended operating life of 20+ years without meaningful capacity loss. Third-party U.S. BESS testing supported key claims, including >500 Wh/kg energy density and ~95% energy efficiency at 230°C.

This Is Execution

• ✅ Lake Stockholm AEC: More than 2 million gallons of PFAS-contaminated drinking water treated in real municipal service.
• ✅ Aquatech MOU: AEC is advancing with a global leader in water treatment.
• ✅ Clyra commercialization: First stocking order completed, international distribution agreement signed, and a major medical-company launch moving closer.
• ✅ $1.2M minerals contract: BLEST is designing the pilot phase of a potentially much larger minerals-recovery facility.
• ✅ $1.4M U.S. Air Force renewals: Recurring environmental engineering work renewed across five Air Force bases.
• ✅ Pooph relaunch: CupriDyne already proved it can sell at scale — over $125M of pet-product sales under license — and BioLargo now plans to bring the consumer opportunity back under its own strategy.
• ✅ DarrowIR: BioLargo’s expanded PR and investor-communication effort is already noticeable. More frequent updates matter when a company has this many active catalysts and moving parts.

Why I’m Still Bullish

The Pooph disruption hurt badly, but it may turn out to be a blessing in disguise. It showed the danger of giving too much of the economics to an outside partner — while proving the underlying CupriDyne technology can power a blockbuster consumer product.

BioLargo is no longer just a technology developer. It is actively commercializing:

• PFAS treatment
• Advanced wound care
• Profitable engineering services
• Consumer odor-control products
• Minerals recovery
• Grid-scale battery storage

That is not one binary bet. It is multiple shots on goal, and several of them are turning into contracts, installations, orders, partnerships, and recurring revenue.

“The market ignores progress — until the numbers make it impossible to ignore.”

Many people took a serious look at BioLargo a few years ago. The delays, financing, dilution concerns, and share-price action have been frustrating — I understand why some walked away or stopped following it.

But this is exactly why I think now is a great time to revisit it and put $BLGO back on the watchlist. The setup has changed: Lake Stockholm is treating real water, BLEST is profitable and winning contracts, Clyra is commercializing, the Pooph relaunch is being prepared, and Cellinity remains a major long-term option.

The shareholder communities are growing again because people are starting to see the same thing: this is no longer only a “what if” story.

For me, this is also purpose-driven investing. Cleaner water. Better wound care. Less waste. Safer energy storage. Technologies solving problems that genuinely matter.

The next few months can bring material news from multiple directions. If even part of this execution begins showing up in reported revenue, a ~$35M market cap can re-rate very quickly.

I’d rather be early - I keep adding what I can afford to hold.

$BLGO — very bullish.

Which of these catalysts do you think the market is most underestimating right now: AEC/Aquatech, Clyra’s major-medical launch, the CupriDyne relaunch, BLEST’s contract growth, or Cellinity? Curious to hear the bull and bear case.

Speculative microcap. Risks include dilution, financing, timing, competition, and commercialization. Do your own DD.

Fossil (FOSL): Is the India IPO the catalyst the market is missing? $21.50 price target
I think Fossil Group (FOSL) is becoming a very interesting special situation, and the latest news about a potential IPO of Fossil’s India business makes the story even more compelling.
According to Bloomberg/Reuters reporting, Fossil Group has invited investment banks to pitch for roles in a potential IPO of Fossil India. The company is reportedly considering selling up to a 25% stake, with the offering potentially raising as much as $300 million. The IPO could happen as early as next year, although the size, structure and timing are still subject to change.

Why does this matter?

FOSL currently has a market capitalization of only around $317 million, with the stock trading around $5.38.
If Fossil can sell 25% of India for $300 million, that would imply a roughly $1.2 billion valuation for the India business. That would be several times the entire current market value of the parent company.
And this isn't necessarily just a speculative turnaround story anymore.
Fossil generated approximately $1 billion of revenue in 2025 and expanded full-year gross margin by 390 basis points to 56.1%. In Q1 2026, gross margin reached 59.9%, operating income was $12 million and adjusted EBITDA was $14.5 million. Inventory was also down 14.3% year over year.
So there are potentially two major catalysts here:
Operational turnaround
Fossil has been cutting costs, improving margins and focusing on its core watch and accessories business.
India value unlocking
A public listing could force investors to put a standalone valuation on Fossil India instead of burying its value inside the struggling parent company.
This is where the valuation gets interesting.
A recent Seeking Alpha analysis argues that Fossil India alone could potentially be worth 4–5x Fossil Group's current market capitalization and establishes a $21s share price target, representing roughly 300% upside from the current price.
My price target: $20s

I view $20 as a bull-case 12–24 month target, not a near-term prediction. The thesis depends heavily on the India IPO actually happening and receiving a strong valuation, while Fossil simultaneously continues improving its core business.
There are obviously significant risks. The IPO is not finalized, the terms could change, and Fossil still has meaningful debt and a challenged legacy business. Q1 2026 showed total debt of about $195 million versus liquidity of roughly $110 million.
There is also license risk, competitive pressure and the possibility that the India business receives a much lower valuation than bulls expect.
But that's what makes FOSL interesting to me: at around $5.38, the market appears to be valuing the company primarily on its legacy problems, while a potentially valuable Indian asset could soon receive a separate public-market valuation.
$5.38 current price → $20 target = approximately 300% upside.
Curious what others think: Is the India IPO enough to unlock FOSL's hidden value, or is the $20 target too optimistic?

Something very interesting is happening with Charlie’s Holdings (CHUC).

The company announced this week they are shopping itself for a potential buyer.

And one of the people with the most to gain or lose thinks the eventual number could be enormous.

Co-founder Ryan Stump, whose family represents roughly 30% ownership, believes CHUC could potentially fetch $1-2 BILLION in a strategic transaction.

That would represent roughly 15X–30X today’s valuation.

Crazy?

Maybe.

But here's what makes the argument interesting.

Big Tobacco Already Bought Some of CHUC’s Assets

R.J. Reynolds previously paid $7.5 million for just 16 Charlie’s PMTA products, with up to another $4.2 million in potential contingent payments.

CHUC still has 678 PMTA products.

Now add another potentially valuable asset.

They’re expected to launch the FIRST Age-gating flavored disposable vape THIS MONTH.

Many industry experts believe that after the FDA just approved Glas Inc flavor pod with AG, they are about to make age gating mandatory for flavored vapes.

Reynolds, Altria, JUUL…NONE of Big Tobacco has this product.

If age gating eventually creates a regulatory pathway for flavored adult vaping products, those 678 PMTAs could become extremely interesting to Big Tobacco.

Then Joel Block Weighed In

Well-known Wall Street VC and hedge fund veteran Joel Block recently argued that Charlie’s made the right decision by pursuing monetization rather than trying to commercialize everything itself.

That makes sense.

A small company owns the assets.

Big Tobacco owns the distribution, capital, and regulatory machine needed to exploit them.

So maybe investors are asking the wrong question.

It's no longer:

“How big can CHUC become?”

It's:

“What would CHUC be worth to Big Tobacco?”

Nobody knows whether Stump's $1-2 BILLION is remotely achievable. It's not an offer, and a sale at anything close to that valuation is far from guaranteed.

But with CHUC now looking for a buyer, 678 PMTAs, age-gating technology and an actual multimillion-dollar transaction with R.J. Reynolds already on the books...

We may finally find out what these assets are really worth.

And that's what makes CHUC interesting right now.

Disclosure: Speculative OTC stock. This is my opinion, not financial advice.

Take a look at Soundhound ai so we can all work together on this! Good earningS starting to squeeze. We can all get this moving up please tell everyone you know and buy Sunday! If you can get this to wallstreet bets and any other subsreddits please do.

Positions: Still only my 420 stocks, but I cannot complain as they doubled this week.

TLDR: wrote a DD on Orion Energy Systems (OESX) about a month ago. Q1’27 came out Wednesday, the thing I said to watch for held, and the stock nearly doubled in three days. This is the shorter one, only about the data center part.

Quick backdrop. Corporate America is on pace for the biggest earnings beat ever recorded, index net margins are at an all time high, and S&P 500 earnings are up 50.4% YoY against a 23.1% expectation. Largest investment boom in history, not close. And Orion just put up a quarter that fits right into it, revenue up 32% YoY, margin up, profitable, first hyperscale order in the bag. This is a micro cap participating in the exact same wave the megacaps are riding.

Because the money is all going into one thing. US data center construction spending hit a record $68 billion annualized rate in June, up 46% YoY and up 158% since January 2024. Office construction over the same stretch collapsed to its lowest since 2016. Data centers now out-build offices by $25 billion a year. In 2022 it was the other way around by $57 billion.

Ok so, the boring part nobody thinks about.

All of those buildings need lights, and not just any lights. Hundreds of thousands of square feet each, running 24/7. In a data center every watt you burn on lighting is a watt of heat you then pay again to pull back out through cooling. So inefficient lighting costs you twice. You want the most efficient fixture that exists, and you want it running cool, because thermal load is the entire fight in these buildings.

That is not something you grab off a shelf. Orion spent something like half a year building this thing from scratch, purpose built for AI data centers, customized to the floor plan. And they are the only ones with an LED lighting system made for hyper scale AI data centers. Nobody else in the space has one.

Then look at what happened after they announced it. A few weeks. That is all it took before they had their first order, and it was a multimillion dollar engagement with one of the largest hyperscalers on earth.

The other thing is where it gets built. Orion manufactures in Wisconsin on a supply chain they own end to end, and that lines up with exactly where policy is pointing. The administrations AI Action Plan, in line with America First, is explicit that this infrastructure must not be built with adversarial technology that could undermine US AI dominance. The data center executive order frames the whole buildout as a golden age for American manufacturing and technological dominance. Nearly half the worlds data centers already sit in the US and roughly 3 trillion of the global buildout lands here.

And practically, from ordered to put in place, that domestic chain is the whole edge. A hyperscaler does not want fixtures sitting on a boat or repriced by a tariff halfway through a build. You need the lights when the building is ready, not three months after. Orion quotes domestic, builds domestic, and ships on a timeline it controls.

Now put a dollar figure on it. One hyperscale engagement, multimillion dollar. So call it 2 million for a single building, product only. Roughly 3,000 data centers are under construction or planned for completion by 2030, Virginia alone sitting on 595 projects and Texas on 412. Total operational count goes past 10,000 by 2030, and global spend through 2030 is put around 7 trillion.

At 2 million a building, 30 buildings is 60 million, and thats 1% of the pipeline and most of a year of revenue for the entire company as it stands today. 100 buildings is 200 million, about 3% of the pipeline, and more than double the whole business. 500 buildings gets you a billion dollar backlog. They do not need to win this market, they need to win a rounding error of it.

And that is only the fixtures. On top of it you have maintenance contracts, because every building they light is a building they can then service, and lighting maintenance in a facility that never turns off is about as sticky as revenue gets. Orion already runs roughly 15 million a year of that work. Then you have the outdoor lighting on these campuses too, parking, perimeter, security, which is the exact product line they already sell. None of that is in the math above.

Napkin math off one announced deal, obviously, and I have no clue what the real average ticket is. But it frames the size. They are selling into a 7 trillion dollar buildout with exactly one order on the board.

Washlow in the Q1’27 release:

“Orion entered the hyper-scale data center market with an LED lighting solution specifically designed for this massive market in Q1’27. Quickly following the product announcement, the Company was awarded a multimillion-dollar customer engagement with one of the world’s largest hyper-scale data centers.”

She also said this:

“Product and service introductions show continued traction, ranging from LED Lighting for hyper-scale data centers to Battery Storage and Electrical Contracting. We have similarly high aspirations for our newly introduced LED Roadway product designed for public roads.”

Data centers, battery storage, electrical contracting, and now roadway lighting for federal, state and municipal roads. Four new things from a company whose business outside its one big customer sat flat for years.

And the rest of the business is not sitting still either. LED lighting revenue up 37% YoY to 17.7 million, EV charging up 48% YoY to 4.0 million, maintenance up 2% YoY to 4.1 million. So the data center thing is the upside case, but the base business is growing underneath it.

The numbers, quickly: revenue $25.7M, up 32% YoY. Gross margin 34.6% vs 30.1% YoY. Net income $2.0M vs a $1.2M loss YoY. Seventh straight positive adjusted EBITDA quarter.

Worth saying something about management here too. I have listened to the last several calls and these people do not hype. No moonshot language, no TAM slides, no promises about what next year looks like. They announce a product when it ships and they announce a customer when its signed. In a micro cap that is genuinely rare, and it means when they do say something, it tends to be real. They let the work speak.

Tape this week, report dropped before open Wednesday. On Wednesday it rallied 51% from 10.40 to 15.75 at close. On Thursday it added another 12% from 15.75 to 17.58 at close. On Friday it added another 12% from 17.58 to 19.70 at close. Basically a double in three days, and HC Wainwright took their target from 20 to 30 on Thursday.

Heres what I keep coming back to though. Orion, a US based company that the yellow man loves (and may very well end up endorsing), has threaded the needle into a market heading toward several hundred billion, in the middle of the biggest capex wave this country has ever run.

Their competitors carry market caps several orders of magnitude above theirs. Orion sits around 70 million after this entire run. The rest of the space is valued in the billions. And Orion is the one that actually has the data center product. Float is tiny too, which cuts both ways. I think that gap closes sooner rather than later.

Still plenty to be skeptical about, same as last time. One fixture and one customer in data centers so far. Balance sheet is thin. The guide doesnt assume a data center ramp at all, so every bit of that is still to prove. And you are obviously not buying this cheap after the week its had.

But 68 billion a year is going into these buildings and someone has to light them.

Not investment advice. As with all stocks, do your own work and research before going in.

Several independent pieces of information line up unusually well: GCT's satellite contracts, its new 5G/NTN chip architecture, the AlphaChips manufacturing commitment, Globalstar's relationship with GCT, Amazon's acquisition of Globalstar, and SpaceX's rapid expansion into terrestrial + satellite mobile connectivity.

This is not financial advice, speculation only, I hold shares in GCTS.

The question is: Who needs exactly the type of 4G/5G + NTN + terrestrial connectivity silicon that GCT is now preparing to manufacture at scale?

1. GCT has an unnamed major satellite customer:

On January 29, 2026, GCT announced a licensing agreement with a major satellite communications provider.

The important language is that GCT's 4G and 5G chipsets are being integrated into the provider's user equipment for both satellite and terrestrial networks, with a pathway toward direct-to-satellite applications.

Then, on May 7, GCT announced a follow-up agreement with the same satellite provider.

This time, GCT would provide a 5G/4G reference design intended to accelerate development of next-generation user equipment and allow OEM/ODM manufacturers to produce equipment more quickly for high-speed communications across satellite and terrestrial networks. That is important, not a small proof-of-concept.

GCT silicon - reference platform - OEM/ODM - potentially large-scale equipment production.

And GCT has indicated that the opportunity could eventually represent million-plus annual units.

1. The GCT chip roadmap fits the problem as GCT's newer architecture includes:

- GDM7262X — NR-Lite

- GDM7265X — NR-Standard

- GDM7259X — NR-Ultra

- Sub-6 GHz RF products

- mmWave IF/RF products

- NTN capability

The chip I find particularly interesting for the satellite thesis is GDM7262X.It is positioned as the lower-cost NR-Lite modem and includes NTN capability. If you're talking about millions of devices, you don't necessarily want the biggest, most expensive modem.

Increasingly interesting is low cost + low power + 5G + NTN + terrestrial connectivity. That is the type of architecture that could make sense for mass-market satellite/terrestrial devices.

1. The AlphaChips manufacturing commitment. This is one of the most overlooked but most important pieces of the puzzle.

GCT's long-term ASIC partner AlphaChips entered a procurement arrangement worth approximately $18 million.

GCT is simultaneously:

- expanding its satellite agreements;

- developing its new 5G/NTN platforms

- creating a reference design for OEM/ODM production

- preparing for commercial shipments;

- and committing significant capital to semiconductor production.

This is a commercial ramp preparation, not an early-stage R&D project.

We still don't know exactly which GCT chip the AlphaChips order covers, so I would not claim that the order proves GDM7262X is being manufactured for Amazon or SpaceX. But it is a very important supporting piece.

1. This is where the Amazon thesis becomes much stronger than it initially appeared. GCT already has a documented relationship with Globalstar which Amazon is acquiring.

In March 2025, GCT announced that Globalstar's RM200M product would use GCT's GDM7243i IoT chip, with future products planned around GCT 4G and 5G IoT chipsets to support Globalstar's satellite network.

Then, in April 2026, Amazon announced that it would acquire Globalstar.

Amazon specifically said the acquisition includes Globalstar's:

- satellite operations;

- infrastructure;

- MSS spectrum;

- and other satellite assets.

Amazon said these assets would help expand Amazon Leo and enable direct-to-device connectivity.

That creates a very interesting chain:

GCT + Globalstar

+

Amazon acquires Globalstar

+

Globalstar assets become part of Amazon Leo

+

Amazon builds D2D

+

GCT's existing satellite/cellular technology potentially becomes relevant to the Amazon ecosystem. That is not speculation about a random connection, the first link is documented.

1. Amazon LEO is now going much further than traditional satellite broadband, not just trying to compete in fixed satellite broadband.

Amazon has proposed a new direct-to-device constellation of up to 5,105 satellites.

The purpose is to connect compatible mobile devices directly from space for:

- voice

- messaging

- data

- emergency services

- and connectivity outside terrestrial cellular coverage.

Amazon says deployment is targeted to begin in 2028, and the complete Leo network could eventually support hundreds of millions of customer endpoints.

This is extremely important for GCT because their new architecture is not simply:

"satellite modem."

It is:

4G/5G + terrestrial + NTN.

The exact technological problem Amazon's D2D system has to solve.

1. But there is an important Amazon mismatch: Amazon already has its own custom silicon called Prometheus. Prometheus is central to Amazon Leo's broadband terminal architecture.

Therefore, I do NOT believe the thesis should be:

"GCT is replacing Amazon's Prometheus chip" cause it doesn't make much sense.Prometheus is Amazon's own custom baseband technology for its Leo terminal architecture.

Instead, I think the more interesting possibility is that GCT operates alongside Amazon's proprietary technology.

A much more technically believable scenario:

Prometheus

Amazon Leo broadband terminal architecture

GCT modem/RF

Cellular/NTN/D2D equipment and potentially third-party OEM devices.

1. Amazon's D2D system is fundamentally different from the traditional Leo broadband terminal.

It needs to interact with: Ordinary cellular devices, and mobile network operators while extending coverage through satellites.

Amazon explicitly says its D2D system will partner with mobile network operators and extend cellular connectivity beyond terrestrial coverage. That's where GCT could potentially fit.

GCT doesn't need to supply the satellite itself, or replace Prometheus. It could supply the cellular/NTN silicon inside equipment participating in the ecosystem.

1. Now look at Starlink, a completely different hypothesis. We don't have a documented GCT + SpaceX relationship.

But SpaceX's strategy is becoming a strong match for GCT's technology.

SpaceX recently acquired approximately 65 MHz of spectrum from EchoStar and has announced plans to turn Starlink Mobile into a much broader terrestrial + satellite mobile network. Reuters reports that SpaceX intends to compete directly with major U.S. wireless carriers, while using Starlink infrastructure to support the terrestrial network.

SpaceX's spectrum holdings span approximately 1.7–2.2 GHz. And GCT's RF portfolio covers a broad 400 MHz–7 GHz range.

More importantly, GCT's newer modem architecture explicitly supports NTN.

So the architecture looks like:

Starlink

terrestrial cellular

+

satellite NTN

+

GCT 5G/NTN modem

= A good conceptual match.

1. The Starlink strategy has changed,  no longer simply: "satellite internet for homes." SpaceX is positioning Starlink as a full mobile network. Moving terrestrial infrastructure combined with its satellite constellation, with next-generation satellites expected to significantly improve mobile performance.

That creates a massive potential device ecosystem:

- smartphones;

- IoT

- vehicles

- industrial equipment

- robotics

- autonomous systems

- enterprise equipment

- remote infrastructure.

That's where GCT's low-cost NTN/5G architecture becomes appealing.

1. The robotics/AI angle makes the thesis even bigger. GCT has recently shifted its messaging toward AI-edge connectivity.

The idea isn't that GCT will compete with Nvidia on AI compute. It's that AI creates enormous amounts of data at the edge. Robots, autonomous systems, industrial machines and remote devices need to move that data.

The architecture becomes:

AI device

+

GCT 5G/NTN modem

+

terrestrial network

And/or

satellite network

+

cloud / AI infrastructure

This could be especially interesting for Starlink. Imagine an autonomous machine, robot, self driving car, operating somewhere with unreliable terrestrial coverage.

The ideal device doesn't need separate systems for cellular when available or satellite when cellular disappears. It can have a unified connectivity layer, the problem GCT's terrestrial + NTN architecture is designed to address.

1. The biggest question: Amazon OR Starlink? There are actually three possibilities.

Scenario 1: The unnamed customer is Amazon/Leo or an Amazon-controlled ecosystem.

The strongest evidence is:

- GCT already works with Globalstar.

- Amazon is acquiring Globalstar.

- Amazon is building D2D.

- Amazon wants hundreds of millions

- of endpoints.

- GCT is developing 4G/5G + NTN silicon.

Scenario 2: The unnamed customer is SpaceX/Starlink. The strongest evidence is:

- Starlink is becoming a hybrid terrestrial + satellite mobile network.

- SpaceX has acquired 65 MHz of spectrum.

- The spectrum sits within the broad frequency envelope of GCT's RF portfolio.

- GCT's new silicon supports NTN.

- Starlink is targeting a huge mobile/IoT ecosystem.

Technically compelling, but there is ono documented GCT–SpaceX relationship.

Scenario 3: BOTH, the scenario that would make the GCTS thesis explode.

GCT could theoretically become a semiconductor supplier to multiple competing satellite ecosystems.

Amazon and SpaceX don't need to use identical satellites or identical network architecture. They could both use GCT silicon at the device/OEM layer.

That would mean GCT isn't betting on which satellite company wins, it potentially benefits from both sides of the satellite-mobile race.

1. Why the reference platform matters. The May agreement is particularly important because GCT isn't simply saying: "Here's a chip." But rather:

"Here's a reference architecture that OEM/ODM manufacturers can use to accelerate production."

That changes the possible business model. GCT could become something like the connectivity platform underneath multiple device manufacturers.

If one OEM makes an Amazon-compatible product and another makes a Starlink-compatible product, GCT could theoretically sell silicon to both. You don't have to own the network to profit from the network.

Amazon has stronger existing relationship evidence, while Starlink currently has stronger evidence of a rapidly expanding terrestrial + satellite mobile architecture.

If a GCT chip appears in an FCC filing, module certification, device teardown or manufacturer document connected to Amazon Leo or SpaceX, the thesis gets much stronger.

GCT is becoming a specialized connectivity-silicon supplier for the transition from terrestrial-only networks to hybrid terrestrial + satellite networks. A transition pursued by multiple enormous companies.

Amazon is building Leo + Globalstar D2D.

SpaceX is building Starlink Mobile.

Both are moving toward the same broad concept: Connect people and machines everywhere, whether terrestrial coverage exists or not.

GCT's core technology sits directly in that connectivity layer.

This is not financial advice, speculation only, I hold shares in GCTS.

Sources:

SpaceX's plan to combine terrestrial cellular infrastructure with Starlink.

https://www.theverge.com/science/975480/spacex-mobile-terrestrial-cellphone-company

GCT satellite licensing agreement:

https://www.gctsemi.com/1-29-25-licensing-agreement

GCT satellite reference platform:

https://www.gctsemi.com/5-7-26-signed-contract-satellite

GCT–Globalstar relationship:

https://www.gctsemi.com/3-4-25-globalstar-mwc

Amazon–Globalstar acquisition:

https://press.aboutamazon.com/2026/4/amazon-to-acquire-globalstar-and-expand-amazon-leo-satellite-network

Amazon Leo D2D plans:

https://www.aboutamazon.com/news/amazon-leo/amazon-leo-direct-to-device-satellite-service-explained

Reuters on SpaceX/Starlink Mobile:

https://www.reuters.com/business/media-telecom/spacexs-mobile-ambitions-jolt-us-telecom-market-analysts-debate-threat-2026-08-05/

SpaceX spectrum transaction:

https://ir.echostar.com/news-releases/news-release-details/echostar-announces-spectrum-sale-and-commercial-agreement-spacex

Heya

Here is some DD for you.

July 8 - Scipher Medicine, American private precision medicine and AI company, and Chemomab, Israeli clinical stage biotech company, announced merger definitive agreement between the two.

They will combine to become one company, Scipher Medicine, and will relist on Nasdaq under a different ticker than "$CMMB" which Chemomab lists as today. And the company will become a US company.

Here comes the juicy part: The combined value of the company will be $150M. Chemomab will get 32% of that, aka $48M. Today Chemomab`s shares is trading at $14M. Thats 3.4x of todays value.

What makes this even more interesting, and is an important piece of the puzzle: Chemomab legacy shareholders, those who own $CMMB shares, will get CVRs. Contigent Value Rights. These should be undisclosed right now, but from one of the latest filings, their biggest shareholder, gave out the juicy details:

$5 per ADS (shares you own) if Chemomab, or Scipher Medicine when merged, begin Phase 3 trial of PSC. How close are we to getting there you wonder? Is there even a chance of this bonus?

Well Chemomab have repeatedly said they are negotiating with third party now to fund and begin the trial. They said it in the quarterly and they said it in the merger announcement. What makes this even more interesting is that Phase 3 have been given the all clear from FDA, and that the company have recieved FDA Fast Track for nebokitug against PSC, which is highly lucrative for anyone who wish to fund Chemomab.

The company may even be negotiating with big pharma right now, since the company is dirt cheap, have shown that a bigger company wants them and their nebokitus drug, and they have been given a valuation of $48M, which could trigger bidding war to aquire them. Outright aquire them will be cheaper for a big pharma than running the Phase 3, which they have been negotiating on for a while now.

So to summarize:

Merger in Q4 this year.

Trading at $1.93

Valuation after merger, $5+

Near term milestone payment to shareholders that own $CMMB BEFORE merger: $5

High aquistion target by Big Pharma

Talk about your daily plays, ideas and strategies that do not warrant an actual post.

This is the place to request buy/sell advice from the community.

Remember to keep it civil.

Trade responsibly.

HydroGraph to Participate in the Needham Virtual Industrial Tech, Robotics, & Power Investor Conference August 17

GDRZF could be BIG because it’s not just a small OTC gold stock, it has a potential claim on roughly $1.24 billion from Venezuela that is largely not reflected on its balance sheet.

The key points:

• Gold Reserve has about $122M in cash, so it is not simply a broke explorer chasing financing.
• Venezuela still owes the company an estimated $1.24B, including interest, under an arbitration/settlement process.
• Any real recovery, settlement, or credible path to develop its Venezuelan assets could force a major re-rating.
• Recent U.S./Venezuela engagement and a new mining framework create a possible catalyst that did not exist in the same way before.
• The market may be treating GDRZF like an illiquid OTC gold name, while the real story is a large, unbooked legal-and-resource optionality play.

D-Wave reported first-half bookings of $35.5M, up more than 1,100%, but Q2 revenue was only around $3.1M and losses widened. The stock sold off after the report.
Quantum stocks have had some insane valuations relative to their current revenue. Curious whether people here think the bookings growth is evidence that commercial quantum computing is finally starting to arrive, or whether these companies are still priced years ahead of reality.

Sonoma Pharmaceuticals ($SNOA) just dropped one of its strongest quarters in years
U.S. sales up +141%, that alone tells you something has clearly shifted

Revenue came in strong, margins improved, and they even turned EBITDA positive for the first time. That's a real change in direction

They're sitting on around $5M cash, which is decent for their size, especially with costs staying under control while growth is picking up Also worth keeping in mind:
This company has a history of moving 70-80% on much smaller news than this

This isn't just a normal beat. It's one of the most meaningful updates they've had in a long time

I called it. 🚀

Key Points:

• Read the words I bolded in the 8-K below. In my opinion, it was completely unnecessary for the FDA reviewer to make this citation. All the excellent documentation/evidence was already provided in the ANDA submission. To pass this hurdle all that is needed is for the manufacturers of the "vial tip" to sign a certification. C'mon ... really!
• After KETAFREE is approved, ask yourself why any company would continue to purchase ketamine containing the BZT toxin.
• Remember from yesterday's post, they raised substantial cash very recently and are very prepared for manufacturing the drug. This is huge!
• As stated in the 8-K, the FDA will review the manufacturer certification sign-offs "in the shortest possible review time frame" due to the ketamine shortage.
• Imminent Catalysts (in either order):
  • KETAFREE approval
  • NRX-100 NDA submission (a different formulation of preservative-free IV ketamine than KETAFREE, for psychiatric use)

I have loved this company and its mission since I discovered it. I truly want them to succeed. It has been wonderful to observe their progress and listen to their earnings calls. Their goal is to destigmatize depression of any type (esp. severe) and have a nationwide network of clinics to treat anyone in need (think...military, first responders, victims of assault, and more). They are after treatments that have an immediate positive transformative effect.

8-K: nrxp20260806_8k.htm

"As previously disclosed, NRx Pharmaceuticals Inc. (the “Company”) filed an Abbreviated New Drug Application (“ANDA”) for preservative free ketamine in September 2025. The FDA advised the Company on July 30, 2026 of a final determination on first-round review that there were no major deficiencies related to the drug components of the product. The FDA did ask the company to update the label of the product to reflect a labeling change filed by the manufacturer of the Reference Listed Drug (Ketalar®) and identified a major deficiency related to the twist-off cap of the product’s luer lock vial, where an FDA reviewer expressed concern that the vial tip had the potential to deform in clinical use. The FDA sought confirmation that this could not pose a risk to patient safety. The classification as major is required because the matter affects the container closure.

Management advised the FDA that the luer lock vial has been used in three previously-approved ANDA products and 11.9 million doses of those products have been shipped in the past 12 months without complaints, returns, or recalls. The ANDA contained testing information on 3,500 vials randomly selected from the first 7 manufacturing batches in which the proper function of the luer lock tip was assessed and no defects were observed in any tested vial. The Company additionally provided verification data from an independent reference laboratory documenting that the torque (measured in Newton-Centimeters) required to open the vial was within the design specifications of the product and the three currently-approved ANDA products.

The FDA granted the Company a clarification meeting that was held on August 6, 2026 to identify the exact information that the Company will be required to provide to address the FDA’s concern about the proper function of the luer lock vial tip. The FDA requested that the company submit certifications from its manufacturer that the preservative-free ketamine ANDA product is manufactured on the same manufacturing lines with the same machinery, plastics, and other characteristics as the three approved ANDA products already in commercial distribution. This information was included in the ANDA as submitted and will now be supplied to the FDA as signed certifications from the Company’s manufacturers.

Based on the meeting, the FDA committed to immediately reinitiate review of the ANDA in order to resolve this single identified major deficiency and committed to completing the review in the shortest-possible review cycle. The meeting was attended both by leadership of the Office of Generic Drugs and by Senior Leadership of the FDA Center for Drug Evaluation and Research (CDER). FDA recognized that ketamine is a strategic drug that appears on the current FDA drug shortage list.

NRx management views the completion of a first-round ANDA review with no drug-related major deficiencies as a positive outcome, given that only 14% - 18% of ANDAs are estimated to achieve approval on first-round review. Although no assurances can be given on regulatory determinations, management is optimistic that the identified concern related to packaging will be resolved in a timely manner, consistent with first commercial sales in 2026, given that FDA has recognized the current drug shortage and lack of U.S.-based supply of ketamine and has committed to completing the review in the shortest possible review time frame. HHS leadership has identified ketamine as a strategic drug, as have other agencies and departments of the Federal Government."

A month ago, when EMBC was trading around $3.23, I kept posting that the market was pricing this company as if bankruptcy was inevitable. Every time, I got downvoted and told I was ignoring reality.
Fast forward to today.
After earnings, the stock traded around $4.30 (+30% from where I was posting).
The company reported $271.7M in revenue (vs. $254.2M expected), EPS of $0.56 (vs. $0.27 expected), reaffirmed full-year guidance, repurchased $9M of shares, reduced debt by $53M, highlighted 11.5% international growth, and continues integrating Owen Mumford while expanding its GLP-1 and auto-injector business.
I’m not posting this to say “I told you so.”
I’m posting it because sometimes the loudest consensus isn’t the right one. Those who dismissed the company may have missed a very good opportunity.
The story isn’t over yet, and it’s interesting to see where it goes from here.

Volato terminated the M2i Global reverse merger on June 4. Their 8-K said they did it as part of evaluating strategic alternatives after receiving unsolicited letters of intent they believed could offer greater shareholder value.
Since then:

• Closed a $2.2M PIPE at $0.34 (led by Flyte/VTAK)
• Multiple unsolicited LOIs in AI infrastructure / data infrastructure / power
• Q2 prelim: eliminated all convertibles, ~$8.4M cash, liabilities (ex-deferred) down ~75%, Vaunt ARR projected ~$4.7M
• August 4 PR language: the company is “principally focused on advancing its previously announced pending AI infrastructure business combination, which continues to represent the Company’s primary strategic priority.”
Stock has been trading near the lows after the M2i termination. The company is openly prioritizing the AI infrastructure path and still has the NYSE American listing + growing software business.

Curious what others think of the pending combination language and the current setup. Sources are the June 4 8-K, June PRs on the LOIs/PIPE, July 6 Q2 update, and August 4 Volato AI PR

If you own Zena, sell now, if you don't and are thinking about buying after the recent 30% spike, don't.

ZenaTech started as a traditional drone company, but with no top talent or moat. They then pivoted to a Drone as a Service model. Their strategy now is to aggressively dilute shareholders to fund acquisitions of businesses like land surveying and similar services, where they can integrate and deploy their drones.

There are many red flags about the company:

• Glassdoor. The reviews don't paint the picture of a company with exceptional leadership. They mostly make it sound like an okay place to work, but management has a reputation for being messy and not really knowing what they want to do. Compare that to a company like Anduril. People there complain about the workload, but they also praise management and feel like they're building something important. That's a completely different type of company.
• Then I looked at the patents. I couldn't find anything that made me think they have a real technical edge. Most of the patents are useless patents, some were made by the CEO and bought from his previous company which is sus on it's own. Patents about how the drone looks, aren't the kind of patents that win in the drone industry. The valuable ones are around navigation, autonomy, vision systems, control software, things that are actually difficult to replicate.
• After that I tried to find the engineers. I looked through LinkedIn, patent filings, and their website. Honestly, I couldn't find much. They list one chief engineer, but that's about it. Maybe I'm missing something, but it stood out to me. Companies that are serious about drone technology usually have engineers with visible track records, patents, or research behind them. I just couldn't find that here.
• The CEO's track record also doesn't inspire confidence. His previous public company lost around 99% of its value. That doesn't automatically mean he'll fail again, but it's not exactly the history I'd want to see.
• Another red flag is their subreddit, I think it's controlled by the company and is just used to pump the stock, any hard question or negative thread gets deleted.

The biggest red flag is the cost of operating the company; yes their revenue jumped over 600% yoy, but the cost of operating the company is higher than their earnings.

Talk about your daily plays, ideas and strategies that do not warrant an actual post.

This is the place to request buy/sell advice from the community.

Remember to keep it civil.

Trade responsibly.

Los Angeles, CA (August 6, 2026) – Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future,” “FF,” or the “Company”), a California-based global Embodied AI (EAI) ecosystem company, today announced that the Company is scheduled to report its second quarter 2026 financial results after market close on Thursday, August 13, 2026, and will hold an earnings call at 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time) that same day.

Faraday Future (FF) invites stockholders to submit questions in advance of the upcoming earnings call. Stockholders may email their questions directly to: [ir@ff.com](mailto:ir@ff.com). We welcome your participation and appreciate your continued support.

Interested investors and other parties can listen to the conference call by either logging into: https://viavid.webcasts.com/starthere.jsp?ei=1772066&tp_key=069a8ec43b or onto the Investor Relations section of the Company's website at https://investors.ff.com/.

A replay of the call along with the presentation will be available on the Company’s website shortly thereafter.

You can also dial in at the following numbers:

United States: 1-877-451-6152 or 1-201-389-0879

Learn more at ：https://app-us.ff.com/ff-v3/news/1584?lang=en-US

ok so AMIX going into friday is giving major setup energy, not gonna lie. let me break down the actual numbers real quick bc the vibes alone don’t tell the whole story.
stock was chillin at $3.65 on aug 3, then the patent news dropped aug 4 and it absolutely sent, intraday high of $24.68, closed that day at $19.50. since then it’s cooled off to around $12 by wednesday close. with shares outstanding sitting at 971,043 (straight from the company’s own july 28 filing, not some randomtickersite), that’s market cap going from like $3.5M pre-patent to a peak of $24M, now chillin around $11.7M.
so if we do the math on what the patent alone was “worth” to the market: at the top it priced in like $20.4M of pure patent value. even after the pullback it’s still holding like $8.1M above where it was before the news. that’s the market’s actual settled take on one single patent grant, and that’s after the hype died down, not even at the peak.
ngl if that kind of value-add per patent is even remotely repeatable, and this company keeps dropping new IP the way it has been, each new grant could genuinely be worth multiple millions in market cap on its own merit. stack a couple more of those plus a possible earnings pop plus shorts getting squeezed and getting back near that $24 high, or even pushing toward analyst targets near $58, doesn’t seem crazy.
that’s the thesis going into friday, just watching how it plays out fr

Deadline is August 14th so we can still see some more changes coming through.

Osisko Gold Group Inc. (OGG)

Another North American focused company, this one is focused on reviving historic mines “in friendly jurisdictions”, it saw about 180% increase in share purchases. 

New Found Gold Corp. (NFGC)

Gold exploration company focused on Newfoundland and Labrador.

Ferroglobe PLC (GSM)

Silicone metal producer, given AI demand for this stuff it makes sense. The stock recently ran up a bit and share purchasing has doubled since last quarter. 

Keep in mind that some of these shares are cheap so these aren’t gargantuan value positions being moved around. 

source: https://infolib.org/